Article Sidebar

PDF
Date Published: 21/07/2021
Abstract Views: 948
Views PDF: 365
DOI: https://doi.org/10.51298/vmj.v501i2.538
Issue
Vol. 501 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Thúy Mậu, N. ., Quý Linh, N. ., Khánh Chi, T. ., Văn Quý, V. ., Văn Toàn, L. ., Vân Khánh, T. ., Thành Văn, T. ., & Huy Thịnh, T. . (2021). CLINCAL CASE REPORT: SAFETY AND EFFICACY OF γδT AUTOLOGOUS IMMUNE CELL THERAPY IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 501(2). https://doi.org/10.51298/vmj.v501i2.538

CLINCAL CASE REPORT: SAFETY AND EFFICACY OF γδT AUTOLOGOUS IMMUNE CELL THERAPY IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Nguyễn Thị Thúy Mậu, Nguyễn Quý Linh, Trần Khánh Chi, Vũ Văn Quý, Lê Văn Toàn, Trần Vân Khánh, Tạ Thành Văn, Trần Huy Thịnh

Main Article Content

Abstract

Using γδT autologous immune cells in the treatment of lung cancer is becoming the next important step towards opening up the prospect of providing the best therapies for lung cancer patients in Vietnam. The purpose of this paper is to initially assess the safety and efficacy of γδT autoimmune therapy in the treatment of a non-small cell lung cancer patient with stage IV in Vietnam. Research methodology: clinical case report and retrospective literature. Results: After 3 infusions of γδT autologous immune cells, the patient had a significant improvement in clinical, subclinical as well as diagnostic imaging. Conclusion: γδT autologous immune cell therapy shows high safety and brings positive results in the treatment of lung cancer in particular and other cancers in general.

Article Details

Keywords

γδT autologous immune cell, non-small cell lung cancer

References

1. 900-world-fact-sheets.pdf. (n.d.). Retrieved from https:// gco.iarc.fr/today/ data/factsheets/ populations/ 900-world-fact-sheets.pdf
2. 704-viet-nam-fact-sheets.pdf. (n.d.). Retrieved from https://gco.iarc.fr/ today/data/factsheets/ populations/ 704-viet-nam-fact-sheets.pdf
3. Hallmarks of cancer: the next generation. (2011). cell, (144), 646–674.
4. Tartour E, Zitvogel L. (n.d.). Lung cancer: potential targets for immunotherapy. Lancet Respir Med, (1), 551–563.
5. Braza, M. S., & Klein, B. (2013). Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. British Journal of Haematology, 160(2), 123–132. https://doi.org/10.1111/bjh.12090
6. Kobayashi, H., & Tanaka, Y. (2015). γδ T Cell Immunotherapy—A Review. Pharmaceuticals, 8(1), 40–61. https://doi.org/10.3390/ph8010040
7. Chen, X., Shang, W., Xu, R., Wu, M., Zhang, X., Huang, P., … Pan, S. (2019). Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment. Journal of Translational Medicine, 17. https://doi.org/10.1186/s12967-019-1897-0
8. γδ T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors. (n.d.). Retrieved 27 April 2021, from https://www.spandidos-publications.com/10.3892/ol.2018.8026/abstract
9. E.S. Morrow, A. Roseweir, J. Edwards. (2019). The role of gamma delta T lymphocytes in breast cancer: a review. Transl. Res, (203, pp.88–96).
10. Toia, F., Di Stefano, A. B., Meraviglia, S., Lo Presti, E., Pirrello, R., Rinaldi, G., … Cordova, A. (2019). Γδ T Cell-Based Immunotherapy in Melanoma: State of the Art. Journal of Oncology, 2019. https://doi.org/10.1155/2019/9014607